Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments
Top Cited Papers
- 10 February 2012
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (5), 1288-1305
- https://doi.org/10.1111/j.1476-5381.2011.01729.x
Abstract
Cyclic nucleotide phosphodiesterases (PDEs) that specifically inactivate the intracellular messengers cAMP and cGMP in a compartmentalized manner represent an important enzyme class constituted by 11 gene-related families of isozymes (PDE1 to PDE11). Downstream receptors, PDEs play a major role in controlling the signalosome at various levels of phosphorylations and protein/protein interactions. Due to the multiplicity of isozymes, their various intracellular regulations and their different cellular and subcellular distributions, PDEs represent interesting targets in intracellular pathways. Therefore, the investigation of PDE isozyme alterations related to various pathologies and the design of specific PDE inhibitors might lead to the development of new specific therapeutic strategies in numerous pathologies. This manuscript (i) overviews the different PDEs including their endogenous regulations and their specific inhibitors; (ii) analyses the intracellular implications of PDEs in regulating signalling cascades in pathogenesis, exemplified by two diseases affecting cell cycle and proliferation; and (iii) discusses perspectives for future therapeutic developments.Keywords
This publication has 166 references indexed in Scilit:
- Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110γMolecular Cell, 2011
- Use of a Schizosaccharomyces pombe PKA-repressible reporter to study cGMP metabolising phosphodiesterasesCellular Signalling, 2011
- Phosphodiesterase 8A (PDE8A) regulates excitation–contraction coupling in ventricular myocytesJournal of Molecular and Cellular Cardiology, 2010
- The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulmonary Pharmacology & Therapeutics, 2010
- Cyclic Nucleotide Binding GAF Domains from Phosphodiesterases: Structural and Mechanistic InsightsStructure, 2009
- Cyclic GMP signaling in cardiovascular pathophysiology and therapeuticsPharmacology & Therapeutics, 2009
- Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 InhibitorsChemMedChem, 2009
- PDE4 inhibitors: current statusBritish Journal of Pharmacology, 2008
- Signal transducing membrane complexes of photoreceptor outer segmentsVision Research, 2008
- Selective phosphodiesterase inhibitors: a promising target for cognition enhancementPsychopharmacology, 2008